View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 19, 2022

Sorrento secures Brazil clearance to start Phase IIa long Covid trial

The trial will assess the safety and efficacy of up to three intravenous doses of COVI-MSC administered on alternate days.

Sorrento Therapeutics has secured the Brazilian health regulatory agency ANVISA authorisation to commence a Phase IIa clinical trial of COVI-MSC for treating ‘long haul’ pulmonary compromise following Covid-19 infection, or long Covid.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

COVI-MSC is a human allogeneic adipose-derived mesenchymal stromal cells (MSC) product candidate.

The multicentre, randomised, placebo-controlled trial will analyse the safety and efficacy of up to three intravenous doses of COVI-MSC given on alternate days versus placebo, along with standard of care.

It will have 60 individuals who have been experiencing respiratory issues as a result of a SARS-CoV-2 infection a minimum of three months before enrolment into the trial.

Improvement in the six-Minute Walk Distance (6MWD) test at day 60 following treatment, will be the primary outcome measure of the trial.

Sorrento anticipates this enrolment pace due to the previous broad Covid-19 burden in Brazil; its collaboration with domestic clinical research organisation Synova Health; and present associations with quality medical centres in the country. 

The alliance with Synova Health makes use of quality study centres as well as a dozen centres that have previously taken part in other acute Covid-19 trials of Abivertinib and MSC with Sorrento.

Sorrento Therapeutics chairman and CEO Dr Henry Ji said: “We are very satisfied with the progress made in Brazil so far, and we have developed very strong local relationships in support of multiple studies. 

“We expect this next Phase II study to confirm the clinical benefits for long-hauler patients. Long-hauler syndrome is likely to be the next major challenge for medical systems in a post-Covid era, and we intend to be the leaders in addressing this future unmet need.”

In July last year, the company dosed participants in a Phase II trial of its intranasal drug, COVIDROPS, to treat Covid-19 in the outpatient setting in the UK.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena